By Nate Raymond
(Reuters) – The chief executives of the three largest U.S. drug distributors and a drugmaker have been summoned to appear before a federal judge to discuss a proposal to resolve thousands of lawsuits alleging they fueled the U.S. opioid crisis, a person familiar with the matter said on Thursday.
The order by U.S. District Judge Dan Polster in Cleveland, Ohio, came as distributors McKesson Corp (N:), Cardinal Health Inc (N:), AmerisourceBergen Corp (N:) and Israel-based drugmaker Teva Pharmaceutical (NYSE:) Industries Ltd (TA:) moved to reach a deal ahead of a trial before him that begins on Monday.
Those companies, along with Johnson & Johnson (N:), have been negotiating a settlement they value at roughly $50 billion that would allow them to resolve 2,600 lawsuits nationally by largely states and localities, people familiar with the matter said.
All of those companies except J&J are set to be defendants in the trial before Polster, who oversees the bulk of the litigation. Polster has pushed for a deal that could “do something meaningful to abate this crisis.”
The companies have been discussing the settlement with four state attorneys general whose cases are not before Polster, sources told Reuters on Wednesday. Lawyers for the local governments say they have not decided whether to back it.
Under the proposal, McKesson, AmerisourceBergen and Cardinal Health would pay $18 billion over 18 years and J&J would pay $4 billion, according to two people familiar with the matter.
Teva has offered to give away medications it values at $15 billion as part of an overall deal it values at roughly $28 million under which it would also provide distribution services, the people said.
Spokespeople for Cardinal CEO Michael Kaufmann and AmerisourceBergen CEO Steven Collis declined to say if they would be in Cleveland on Friday. Representatives Teva CEO Kare Schultz and McKesson CEO Brian Tyler did not respond questions of whether they would be in court.
Opioids were responsible for roughly 400,000 overdose deaths in the United States from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
The lawsuits accuse drug manufacturers of deceptively marketing opioids in ways that downplayed their risks, and drug distributors of failing to detect and halt suspicious orders. They deny wrongdoing.
The cases prompted OxyContin maker Purdue Pharma LP to file for bankruptcy protection in September after reaching a tentative deal it says is worth at least $10 billion to resolve the cases.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.